# Project 1: Novel mechanisms driving mucin secretion and mucus plugging in type 2-high asthma

> **NIH NIH U19** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $468,300

## Abstract

PROJECT 1 SUMMARY
Mucus plugging is a major cause of cause of airway obstruction, morbidity, and mortality in severe asthma. Work
performed in our Center has helped to establish a strong association between type 2 inflammation and mucus
plugging and has revealed that direct effects of the type 2 cytokine IL-13 on airway epithelium induce changes
in the composition and organization of mucus that result in plugging. The overall objective of this project is to
understand novel molecular mechanisms that alter secretory cell and mucus function in asthma. In Aim 1, we
will build on new preliminary data showing that the IL-13-inducible goblet cell protein, tetraspanin 8 (TSPAN8) is
required for stimulated mucin release. Based upon our results and existing information about other tetraspanins,
we hypothesize that TSPAN8-enriched microdomains in goblet cells play critical roles in mediating intracellular
signals required for mucin secretion and in the organization and function of mucin-containing secretory granules.
We will test this hypothesis using primary human bronchial epithelial cells and in a mouse model, which will allow
us to determine the importance of this molecule in vivo. In Aim 2, we will investigate the impact of cathepsin
cysteine proteases and their inhibitors on mucus. Cystatin SN and cystatin S are human cysteine protease
inhibitors (absent in mice). We found that these cystatins are strongly induced by IL-13 and in type 2-high asthma
and that CRISPR targeting either cystatin or addition of excess cathepsin to mucus prevents IL-13-induced
impairments in mucociliary clearance. We hypothesize that these cystatin SN and cystatin S impair mucociliary
clearance by inhibiting cathepsin-mediated degradation of mucins and activation of ENaC, a channel that is
important for mucus hydration and mucociliary transport. We will test this hypothesis by using in vitro assays to
study the biochemical functions of relevant cathepsins and cystatins and by assessing the physiologic role of
these molecules in the primary HBEC culture model. In Aim 3, we will test whether mucus plugging in lung
specimens from individuals with asthma is associated with strong local type 2 immune responses and prominent
IL-13-related epithelial changes. Preliminary data from our Center and others is consistent with the hypothesis
that mucus plugging occurs in the setting of a strong local type 2 immune response and strong epithelial cell
induction of the mucin MUC5AC after exposure to IL-13. We will test this hypothesis by comparing IL-13
responses in epithelial cells from individuals with asthma and controls and by collaborating closely with the
Clinical Subject and Biospecimen Processing and Analysis Core to obtain detailed spatial cellular and
transcriptional data about immune and epithelial states associated with mucus plugs. The impact of this work
will be to substantially advance our understanding of known and novel pathways responsible for formation and
persistence of ...

## Key facts

- **NIH application ID:** 10809783
- **Project number:** 5U19AI077439-17
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** David J Erle
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $468,300
- **Award type:** 5
- **Project period:** 2008-04-01 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10809783

## Citation

> US National Institutes of Health, RePORTER application 10809783, Project 1: Novel mechanisms driving mucin secretion and mucus plugging in type 2-high asthma (5U19AI077439-17). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10809783. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
